Highlights Sihuan Pharmaceutical Holdings Group Ltd. Shanghai - Hong Kong Stock Connect

Equities

460 BMG8162K1137

Highlights

Unlock all the news: Be the first to know and act before the market!

Sihuan Pharma Unit's Microvascular Disease Drug Gets China Registration Approval	06-27	MT
Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration	06-26	CI
Sihuan Pharmaceutical Holdings Group Ltd. commences an Equity Buyback Plan for 932,999,920 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.	06-24	CI
Sihuan Pharma Subsidiary Licenses Fadanafil Drug to Livzon Pharmaceutical Unit	06-13	MT
Xuanzhu Biopharmaceutical Co., Ltd. and Livzon Group Livzon Pharmaceutical Factory Reaches an Exclusive Licensing Cooperation on Fadanafil	06-13	CI
Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA	06-11	CI
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic	06-06	RE
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China	06-06	RE
Sihuan Pharmaceutical, Unit Withdraw Latter's Stock Exchange Bid, Shares Down by Over 3%	05-27	MT
Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10%	05-02	MT
Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government	04-25	MT
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments	03-29	MT
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China	03-25	MT
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug	01-23	MT
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets	01-22	CI
China Includes Four Injectables by Sihuan Pharma Associate in Drug Reimbursement List; Shares Rise 3%	01-10	MT
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes	01-08	CI
China's Medical Products Administrator Approves Sihuan Pharma Unit's Diabetes Drug	25/10/23	MT
National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical	24/10/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sihuan Pharmaceutical Holdings Group Ltd. Shanghai - Hong Kong Stock Connect

Equities

460

BMG8162K1137

Highlights

Filters